Rituximab Initiation and Dosing Protocol

For most rheumatic and autoimmune conditions, initiate rituximab with two 1,000 mg IV infusions separated by 2 weeks, following mandatory pre-treatment screening and standardized premedication to prevent infusion reactions. 1

Pre-Treatment Safety Screening (Mandatory)

Before initiating rituximab, obtain the following baseline assessments 2, 3:

Hepatitis B virus screening: HBsAg, anti-HBs, and anti-HBc (critical—reactivation can be fatal)
Hepatitis C antibodies
Latent tuberculosis screening
Complete blood count with differential
Baseline immunoglobulin levels (IgG, IgM, IgA)
Comprehensive metabolic panel (renal function assessment)

Critical caveat: For HBsAg-positive patients or those with anti-HBc positivity, antiviral prophylaxis with entecavir or tenofovir should be initiated 2-4 weeks before rituximab and continued for 12 months after the last dose due to prolonged risk of hepatitis B reactivation 4. This extended prophylaxis period is unique to rituximab compared to other immunosuppressants.

Standard Premedication Protocol

Administer 30-60 minutes before each infusion 1:

Methylprednisolone 100 mg IV (or equivalent corticosteroid)
Acetaminophen 650-1,000 mg oral
Diphenhydramine 50 mg IV (or equivalent H1 antihistamine)
Consider ranitidine 50 mg IV (H2 blocker) for additional protection
For patients with respiratory disease (asthma, reduced FEV1): add albuterol inhaler/nebulizer

Induction Dosing Regimens by Indication

Vasculitis (GPA/MPA) - Adults

Induction: 5, 1

375 mg/m² IV weekly for 4 weeks, OR
1,000 mg IV on days 1 and 15 (preferred for convenience)
Must be combined with glucocorticoids: methylprednisolone 1,000 mg IV daily for 1-3 days, followed by oral prednisone taper

Maintenance (after achieving remission): 5, 1

500 mg IV every 6 months (FDA-approved), OR
1,000 mg IV every 4 months (alternative based on clinical trials)
Continue for at least 18-24 months or based on clinical evaluation

Vasculitis (GPA/MPA) - Pediatric

Induction: 1, 6

375 mg/m² IV weekly for 4 weeks
Preceded by methylprednisolone 30 mg/kg IV (max 1,000 mg/day) for 3 days

Maintenance: 1

250 mg/m² IV on days 1 and 15, then 250 mg/m² every 6 months

Inflammatory Myopathies (Dermatomyositis/Polymyositis)

1,000 mg IV repeated on day 15 (preferred), OR
375 mg/m² IV weekly for 4 weeks

Pemphigus Vulgaris

Induction: 1,000 mg IV on days 1 and 15 with glucocorticoid taper
Maintenance: 500 mg IV at month 12, then every 6 months
Relapse treatment: 1,000 mg IV (no sooner than 16 weeks after previous dose)

Interstitial Lung Disease (SARD-ILD)

1,000 mg IV every 2 weeks for 2 doses
May repeat every 24 weeks as needed

Infusion Administration Details

First Infusion Protocol

1, 7

Standard infusion (first exposure):

Dilute to 1-4 mg/mL in 0.9% NaCl or 5% dextrose
Start at 50 mg/hour, increase by 50 mg/hour every 30 minutes if tolerated
Maximum rate: 400 mg/hour
Total duration: typically 4-6 hours for first infusion

Critical monitoring period: First 30-120 minutes (highest risk for infusion reactions—occurs in 32% of patients on first exposure) 7

Subsequent Infusions

1, 8

For patients who tolerated the first infusion without grade 3-4 reactions:

90-minute infusion protocol can be used (after first full-rate infusion tolerated)
30-minute rapid infusion is safe after tolerating 90-minute infusion 8
Infusion reactions drop dramatically after first exposure (typically <5% with subsequent doses)

Prophylactic Medications During Treatment

PCP Prophylaxis (Mandatory)

Start: Before or with first rituximab dose
Duration: Throughout treatment and for at least 6 months after last dose (12 months for CLL patients)
Agent: Trimethoprim-sulfamethoxazole preferred (or alternative if contraindicated)

Herpes Virus Prophylaxis

Consider for high-risk patients (CLL, heavily immunosuppressed)
Duration: During treatment and up to 12 months after

Monitoring Schedule

During Treatment

CBC with differential: Baseline, then every 2-4 months
Renal function: Before each infusion and at regular intervals
Monitor for infusion reactions: Especially during first infusion
Immunoglobulin levels: Periodically (risk of hypogammaglobulinemia with repeated courses)

Post-Treatment Surveillance

Continue monitoring for up to 12 months after last dose for:
- Infections (including PML—rare but potentially fatal)
- Hepatitis B reactivation (if risk factors present)
- Cytopenias

Maintenance vs. Retreatment Strategy

For vasculitis: Scheduled maintenance dosing every 6 months is strongly preferred over ANCA-titer or B-cell guided retreatment 5. This provides superior disease control and prevents relapses more effectively than waiting for biomarker changes.

For lymphomas/other conditions: The evidence supports both scheduled maintenance and retreatment at progression, with maintenance showing longer time to treatment failure 9.

Vaccination Timing (Critical)

Ideally: Complete all vaccinations before starting rituximab
If already on rituximab:
- Time non-influenza vaccines for when next rituximab dose is due
- Hold rituximab for at least 2 weeks after vaccination to allow immune response
- Influenza vaccine: give on schedule, delay subsequent rituximab dose by 2 weeks if disease allows

Common Pitfalls to Avoid

Inadequate hepatitis B screening: This is non-negotiable—reactivation can be fatal and occurs up to 1-2 years after last dose
Insufficient premedication: Skipping corticosteroid premedication significantly increases infusion reaction risk
Premature rapid infusion: Never use rapid infusion protocols on first exposure
Inadequate PCP prophylaxis duration: Must continue 6-12 months after last dose, not just during active treatment
Using B-cell counts to guide maintenance in vasculitis: Scheduled dosing is superior to biomarker-guided approaches 5

What is the appropriate initiation protocol and dosing regimen for rituximab, including required safety labs, premedication, induction dosing, and maintenance schedule?

Have a follow-up question?